Marksans Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. The company will acquire entire shareholding of ABCnow GmbH for a total consideration of ? 892,384.

The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.

This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in the European markets.

Headquartered in Flensburg, ABCnow GmbH is a pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. It has a turnover of euro 227,233.69 as on 31 December 2025.

Marksans will acquire entire shareholding of ABCnow GmbH for a total cash consideration of euro 892,384. The acquisition is expected to be completed by 31 July 2026.

Offering the rationale for this acquisition, Marksans Pharma stated that this acquisition will enable the company to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans? presence in the European markets.

Marksans Pharma is engaged in the research, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets, with a strong presence in OTC and prescription products.

The company had reported 63.59% increase in consolidated net profit to Rs 148.13 crore on a 20.84% rise in revenue to Rs 856.11 crore in Q4 FY26 as compared with Q4 FY25.

Powered by Capital Market - Live News

Marksans Pharma announced that the 34th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Marksans Pharma has completed the acquisition of 100% share capital of QliniQ B.V. based in the Netherlands.